MedTrace Logo

An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy

NCT01568190 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2015-01-06

No results posted yet for this study

Summary

The purpose of the trial is to assess the tolerability of the up-dosing phase of AVANZ Mite mix.

Conditions

  • Allergic Rhinitis Due to Dust Mite

Interventions

BIOLOGICAL

AVANZ MITE

Immunotherapy Dermatophagoides mix

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • ANA I TABAR, MD · HOSPITAL VIRGEN DEL CAMINO - PAMPLONA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01568190 on ClinicalTrials.gov